Troglitazone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Troglitazone" in English language version.

refsWebsite

Global rank English rank

14nih.gov

4^th place

12doi.org

2^nd place

3nytimes.com

7^th place

3pulitzer.org

2,337^th place

1,511^th place

2latimes.com

22^nd place

19^th place

2fda.gov

447^th place

338^th place

1books.google.com

3^rd place

1wired.com

193^rd place

152^nd place

1semanticscholar.org

11^th place

8^th place

1apnews.com

129^th place

89^th place

1icis.com

low place

1web.archive.org

1^st place

1bbc.co.uk

8^th place

10^th place

1nyu.edu

1,174^th place

773^rd place

1bloomberg.com

99^th place

77^th place

apnews.com

"Report: FDA Removes Medical Officer". Associated Press.

bbc.co.uk

news.bbc.co.uk

"Diabetes drug withdrawn from sale". BBC. British Broadcasting Corporation. 1 December 1997. Retrieved 12 December 2012.

bloomberg.com

Feeley J (March 31, 2009). "Pfizer Ends Rezulin Cases With $205 Million to Spare". Bloomberg. Retrieved 6 April 2014.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495.

doi.org

Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P (July 2001). "Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?". The Journal of Clinical Endocrinology and Metabolism. 86 (7): 3250–3256. doi:10.1210/jcem.86.7.7564. PMID 11443197.
Cohen JS (June 2006). "Risks of troglitazone apparent before approval in USA". Diabetologia. 49 (6): 1454–1455. doi:10.1007/s00125-006-0245-0. PMID 16601971.
Henry RR (September 1996). "Effects of troglitazone on insulin sensitivity". Diabetic Medicine. 13 (9 Suppl 6): S148 – S150. doi:10.1002/dme.1996.13.s6.148. PMID 8894499. S2CID 34080394.
Keen H (November 1994). "Insulin resistance and the prevention of diabetes mellitus". The New England Journal of Medicine. 331 (18): 1226–1227. doi:10.1056/NEJM199411033311812. PMID 7935664.
The Diabetes Prevention Program Research Group (April 1999). "The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes". Diabetes Care. 22 (4): 623–634. doi:10.2337/diacare.22.4.623. PMC 1351026. PMID 10189543.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (February 2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". The New England Journal of Medicine. 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527.
Gale EA (January 2006). "Troglitazone: the lesson that nobody learned?". Diabetologia. 49 (1): 1–6. doi:10.1007/s00125-005-0074-6. PMID 16362281.
Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, et al. (January 2001). "Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission". Chemical Research in Toxicology. 14 (1): 62–70. doi:10.1021/tx000180q. PMID 11170509.
Funk C, Ponelle C, Scheuermann G, Pantze M (March 2001). "Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat". Molecular Pharmacology. 59 (3): 627–635. doi:10.1124/mol.59.3.627. PMID 11179459.
Dixit VA, Bharatam PV (July 2011). "Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study". Chemical Research in Toxicology. 24 (7): 1113–1122. doi:10.1021/tx200110h. PMID 21657230.
Masubuchi Y (October 2006). "Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review". Drug Metabolism and Pharmacokinetics. 21 (5): 347–356. doi:10.2133/dmpk.21.347. PMID 17072088.
Salamone S, Colin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Flament S, et al. (May 2012). "Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study". European Journal of Medicinal Chemistry. 51: 206–215. doi:10.1016/j.ejmech.2012.02.044. PMID 22409968.

fda.gov

accessdata.fda.gov

"Approval package for Rezulin (troglitazone)" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration. 4 April 1997. Archived from the original (PDF) on 5 November 2014.

fda.gov

"2000 Safety Alerts for Human Medical Products". U.S. Food and Drug Administration. Retrieved 12 December 2012.

icis.com

Sinclair N (31 July 1997). "Glaxo Wellcome gets approval for Romozin". ICIS News. Retrieved 12 December 2012.

latimes.com

Willman D (4 June 2000). "The Rise and Fall of the Killer Drug Rezulin". The Los Angeles Times. Retrieved 12 December 2012.
Willman D (March 17, 2000). "Physician Who Opposes Rezulin Is Threatened by FDA With Dismissal". Los Angeles Times.

nih.gov

pubmed.ncbi.nlm.nih.gov

Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P (July 2001). "Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?". The Journal of Clinical Endocrinology and Metabolism. 86 (7): 3250–3256. doi:10.1210/jcem.86.7.7564. PMID 11443197.
Cohen JS (June 2006). "Risks of troglitazone apparent before approval in USA". Diabetologia. 49 (6): 1454–1455. doi:10.1007/s00125-006-0245-0. PMID 16601971.
Henry RR (September 1996). "Effects of troglitazone on insulin sensitivity". Diabetic Medicine. 13 (9 Suppl 6): S148 – S150. doi:10.1002/dme.1996.13.s6.148. PMID 8894499. S2CID 34080394.
Keen H (November 1994). "Insulin resistance and the prevention of diabetes mellitus". The New England Journal of Medicine. 331 (18): 1226–1227. doi:10.1056/NEJM199411033311812. PMID 7935664.
The Diabetes Prevention Program Research Group (April 1999). "The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes". Diabetes Care. 22 (4): 623–634. doi:10.2337/diacare.22.4.623. PMC 1351026. PMID 10189543.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (February 2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". The New England Journal of Medicine. 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527.
Gale EA (January 2006). "Troglitazone: the lesson that nobody learned?". Diabetologia. 49 (1): 1–6. doi:10.1007/s00125-005-0074-6. PMID 16362281.
Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, et al. (January 2001). "Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission". Chemical Research in Toxicology. 14 (1): 62–70. doi:10.1021/tx000180q. PMID 11170509.
Funk C, Ponelle C, Scheuermann G, Pantze M (March 2001). "Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat". Molecular Pharmacology. 59 (3): 627–635. doi:10.1124/mol.59.3.627. PMID 11179459.
Dixit VA, Bharatam PV (July 2011). "Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study". Chemical Research in Toxicology. 24 (7): 1113–1122. doi:10.1021/tx200110h. PMID 21657230.
Masubuchi Y (October 2006). "Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review". Drug Metabolism and Pharmacokinetics. 21 (5): 347–356. doi:10.2133/dmpk.21.347. PMID 17072088.
Salamone S, Colin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Flament S, et al. (May 2012). "Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study". European Journal of Medicinal Chemistry. 51: 206–215. doi:10.1016/j.ejmech.2012.02.044. PMID 22409968.

ncbi.nlm.nih.gov

The Diabetes Prevention Program Research Group (April 1999). "The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes". Diabetes Care. 22 (4): 623–634. doi:10.2337/diacare.22.4.623. PMC 1351026. PMID 10189543.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (February 2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". The New England Journal of Medicine. 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527.

nytimes.com

Fisher L (4 November 1997). "Adverse Diabetes Drug News Sends Warner-Lambert Down". The New York Times. Retrieved 12 December 2012.
Leary W (31 January 1997). "New Class of Diabetes Drug Is Approved". The New York Times. Retrieved 12 December 2012.
Fisher L (17 January 1998). "Drug Makers at Threshold of a New Therapy; With a Dose of Biotechnology, Big Change Is Ahead in the Treatment of Diabetes". The New York Times. Retrieved 12 December 2012.

nyu.edu

people.stern.nyu.edu

"Pfizer Annual Report 2001" (PDF). Pfizer. Retrieved 12 December 2012.

pulitzer.org

Willman D (20 December 2000). "NEW FDA: Rezulin Fast-Track Approval and a Slow Withdrawal". The Los Angeles Times. Retrieved 12 December 2012.
Willman D (16 August 2000). "FDA's Approval and Delay in Withdrawing Rezulin Probed". The Los Angeles Times. Retrieved 12 December 2012.
Willman D (10 March 2000). "Fears Grow Over Delay in Removing Rezulin". The Los Angeles Times. Retrieved 12 December 2012.

semanticscholar.org

api.semanticscholar.org

Henry RR (September 1996). "Effects of troglitazone on insulin sensitivity". Diabetic Medicine. 13 (9 Suppl 6): S148 – S150. doi:10.1002/dme.1996.13.s6.148. PMID 8894499. S2CID 34080394.

web.archive.org

"Approval package for Rezulin (troglitazone)" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration. 4 April 1997. Archived from the original (PDF) on 5 November 2014.

wired.com

Hintertheur A (November 2008). "Retired Drugs: Failed Blockbusters, Homicidal Tampering, Fatal Oversights". wired.com.